IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood

J Invest Dermatol. 2014 Dec;134(12):2990-2993. doi: 10.1038/jid.2014.268. Epub 2014 Jul 7.

Authors

Claire Q F Wang¹, Mayte Suárez-Fariñas², Kristine E Nograles¹, Claudia A Mimoso¹, David Shrom³, Ernst R Dow³, Michael P Heffernan³, Robert W Hoffman³, James G Krueger⁴

Affiliations

¹ Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA.
² Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA; Rockefeller University Center for Clinical and Translational Science, New York, New York, USA.
³ Eli Lilly and Company, Lilly Research Labs, Indianapolis, Indiana, USA.
⁴ Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA. Electronic address: jgk@rockefeller.edu.

PMID: 24999591
DOI: 10.1038/jid.2014.268

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use*
Cells, Cultured
Cytokines / metabolism*
Dose-Response Relationship, Drug
Humans
Infusions, Intravenous
Injections, Subcutaneous
Interleukin-17 / administration & dosage
Interleukin-17 / immunology
Interleukin-17 / pharmacology*
Monocytes / drug effects*
Monocytes / metabolism*
Monocytes / pathology
Psoriasis / drug therapy*
Psoriasis / metabolism*
Receptors, Chemokine / metabolism
Signal Transduction / drug effects
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cytokines
Interleukin-17
Receptors, Chemokine
ixekizumab